| scholarly article | Q13442814 |
| P356 | DOI | 10.1681/ASN.2012020187 |
| P8608 | Fatcat ID | release_vboylrar6za6xkoed6kjdipa3e |
| P932 | PMC publication ID | 3582199 |
| P698 | PubMed publication ID | 23393315 |
| P50 | author | V Michael Holers | Q93110324 |
| P2093 | author name string | Joshua M Thurman | |
| Brandon Renner | |||
| Derek Strassheim | |||
| Liudmila Kulik | |||
| Richard Fuquay | |||
| Danica Ljubanović | |||
| Sarah Panzer | |||
| P2860 | cites work | Progenitors for Ly-1 B cells are distinct from progenitors for other B cells | Q24683187 |
| Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis | Q30541740 | ||
| Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events | Q31442542 | ||
| Depletion of CD4(+) T cells aggravates glomerular and interstitial injury in murine adriamycin nephropathy | Q32082534 | ||
| Pathogenic natural antibodies recognizing annexin IV are required to develop intestinal ischemia-reperfusion injury | Q33646877 | ||
| IgM associated primary diffuse mesangial proliferative glomerulonephritis | Q33848443 | ||
| The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. | Q33943247 | ||
| Blockade of self-reactive IgM significantly reduces injury in a murine model of acute myocardial infarction | Q34062698 | ||
| The double life of a B-1 cell: self-reactivity selects for protective effector functions | Q34154602 | ||
| Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and -Dependent Nephrotic Syndrome | Q34362680 | ||
| Treatment of recurrent focal segmental glomerulosclerosis in pediatric kidney transplant recipients: effect of rituximab. | Q34961453 | ||
| Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial | Q35030581 | ||
| B cell subsets contribute to renal injury and renal protection after ischemia/reperfusion | Q35097477 | ||
| Pathways to nephron loss starting from glomerular diseases-insights from animal models | Q36021181 | ||
| Detection of glomerular complement C3 fragments by magnetic resonance imaging in murine lupus nephritis | Q36034520 | ||
| Innate autoimmunity | Q36037749 | ||
| Immunopathology of the end-stage kidney. Immunoglobulin and complement component deposition in nonimmune disease | Q36077684 | ||
| Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement | Q36366602 | ||
| B cell immunobiology in disease: evolving concepts from the clinic | Q36427357 | ||
| Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury | Q37095150 | ||
| Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis | Q37297636 | ||
| Role of CD5+ B-1 cells in EAE pathogenesis. | Q39706891 | ||
| The many masks of focal segmental glomerulosclerosis | Q40597024 | ||
| Nehprotic syndrome with glomerular mesangial IgM deposits | Q40881538 | ||
| Injury in renal ischemia-reperfusion is independent from immunoglobulins and T lymphocytes | Q43852773 | ||
| Classical pathway of complement activation in normal and diseased human glomeruli | Q44026716 | ||
| Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis | Q44579295 | ||
| Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab | Q46586703 | ||
| Effect of cortisone therapy on serum complement components | Q47976055 | ||
| The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. | Q53863570 | ||
| Clinical and immunopathologic study of mesangial IgM nephropathy: report of 41 cases. | Q54475370 | ||
| Pathologic classification of focal segmental glomerulosclerosis: a working proposal | Q56008651 | ||
| Mice Deficient in Complement Receptors 1 and 2 Lack a Tissue Injury-Inducing Subset of the Natural Antibody Repertoire | Q57331400 | ||
| Immunopathological findings in idiopathic nephrosis: clinical significance of glomerular "immune deposits" | Q67264247 | ||
| Marked proteinuria in hypertensive nephrosclerosis | Q67297236 | ||
| Differential modulation by glucocorticoids of alternative complement protein secretion in cells of the monocyte/macrophage lineage | Q68053989 | ||
| Focal and segmental glomerulosclerosis. Immunohistologic study of 20 renal biopsy specimens | Q68975897 | ||
| Diabetic glomerulonephropathy: histopathologic, immunofluorescent, and ultrastructural studies of 16 cases | Q70231405 | ||
| Immunopathologic Study of Minimal Change Glomerular Disease with Mesangial IgM Deposits | Q70884503 | ||
| No evidence for a specific role of IgM in mesangial proliferation of idiopathic nephrotic syndrome | Q71363863 | ||
| Complement activation products in the urine from proteinuric patients | Q73638841 | ||
| Adult-onset idiopathic nephrotic syndrome associated with pure diffuse mesangial hypercellularity | Q73914322 | ||
| Glomerulopathy with mesangial IgM deposits: long-term follow up of 64 children | Q73943081 | ||
| Complement activation contributes to both glomerular and tubulointerstitial damage in adriamycin nephropathy in mice | Q80209369 | ||
| The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy | Q80375869 | ||
| Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment | Q83283173 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 3 | |
| P304 | page(s) | 393-406 | |
| P577 | publication date | 2013-02-07 | |
| P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
| P1476 | title | IgM contributes to glomerular injury in FSGS | |
| P478 | volume | 24 |
| Q40804668 | Association of apoptosis inhibitor of macrophage (AIM) expression with urinary protein and kidney dysfunction |
| Q35738052 | Classical Complement Pathway Activation in the Kidneys of Women With Preeclampsia |
| Q41022459 | Clinical Significance of IgM and C3 Glomerular Deposition in Primary Focal Segmental Glomerulosclerosis |
| Q57183273 | Clinical significance of mesangial IgM deposition in patients with IgA nephropathy |
| Q54969005 | Complement Activation in Patients With Diabetic Nephropathy. |
| Q35763276 | Complement Activation in Patients with Focal Segmental Glomerulosclerosis |
| Q92327732 | Complement and Complement Targeting Therapies in Glomerular Diseases |
| Q49497379 | Complement factor H protects mice from ischemic acute kidney injury but is not critical for controlling complement activation by glomerular IgM. |
| Q40986583 | Complement in Non-Antibody-Mediated Kidney Diseases. |
| Q50034507 | Complete B Cell Deficiency Reduces Allograft Inflammation and Intragraft Macrophages in a Rat Kidney Transplant Model |
| Q47555950 | Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach. |
| Q90523338 | ECM Characterization Reveals a Massive Activation of Acute Phase Response during FSGS |
| Q38938623 | Focal Segmental Glomerulosclerosis |
| Q37582660 | Focal segmental glomerulosclerosis lagged behind the onset of rheumatoid arthritis by 7 years: A case report and literature review |
| Q64226624 | Glomerular C3 Deposition Is an Independent Risk Factor for Allograft Failure in Kidney Transplant Recipients With Transplant Glomerulopathy |
| Q26773633 | Histological changes of kidney in diabetic nephropathy |
| Q38600476 | IgM as a novel predictor of disease progression in secondary focal segmental glomerulosclerosis |
| Q36016859 | IgM exacerbates glomerular disease progression in complement-induced glomerulopathy |
| Q41023817 | IgM in the kidney: a multiple personality disorder |
| Q38722114 | IgM nephropathy: is it closer to minimal change disease or to focal segmental glomerulosclerosis? |
| Q42956255 | IgM nephropathy: timely response to a call for action |
| Q26753833 | Immunologic Changes Implicated in the Pathogenesis of Focal Segmental Glomerulosclerosis |
| Q51840896 | Investigational drugs in development for focal segmental glomerulosclerosis. |
| Q33419651 | Molecules Great and Small: The Complement System |
| Q35966975 | Plasma Levels of Risk-Variant APOL1 Do Not Associate with Renal Disease in a Population-Based Cohort |
| Q33421493 | Remission of aHUS neurological damage with eculizumab |
| Q33826145 | Serum C3 and Renal Outcome in Patients with Primary Focal Segmental Glomerulosclerosis |
| Q36549551 | Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models |
| Q41250659 | The impact of IgM deposits on the outcome of Nephrotic syndrome in children. |
| Q38244352 | The pathogenesis of focal segmental glomerulosclerosis |
| Q40957838 | World Small Animal Veterinary Association Renal Pathology Initiative: Classification of Glomerular Diseases in Dogs. |
Search more.